View ValuationImugene 향후 성장Future 기준 점검 0/6Imugene 의 수익은 연간 121.9% 감소할 것으로 예상되는 반면, 연간 수익은 29.1% 로 증가할 것으로 예상됩니다. EPS는 연간 56.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -127.1% 로 예상됩니다.핵심 정보29.1%이익 성장률56.23%EPS 성장률Biotechs 이익 성장22.7%매출 성장률-121.9%향후 자기자본이익률-127.14%애널리스트 커버리지Low마지막 업데이트14 May 2026최근 향후 성장 업데이트Breakeven Date Change • Nov 15No longer forecast to breakevenThe 3 analysts covering Imugene no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$150.9m in 2027. New consensus forecast suggests the company will make a loss of AU$50.5m in 2027.Breakeven Date Change • Jun 30Forecast to breakeven in 2027The 3 analysts covering Imugene expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$150.9m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Lesley Cooper was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 30Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 35,445,999 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,220,668 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Mar 11+ 1 more updateImugene Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million.Imugene Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,444 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0072 Security Features: Attached Options공시 • Jan 02Imugene Limited Announces Resignation of Dr. Bradley Glover as Chief Operating OfficerImugene Limited announced that Dr. Bradley Glover has resigned from his position as Chief Operating Officer of Imugene to focus on his other business interests. The Company will manage the transition of responsibilities with no impact on business operations or ongoing programs.공시 • Oct 14Imugene Limited, Annual General Meeting, Nov 13, 2025Imugene Limited, Annual General Meeting, Nov 13, 2025. Location: at automic pty ltd, level 5, 126 phillip street, sydney nsw 2000 Australia공시 • Jul 16+ 1 more updateImugene Limited has filed a Follow-on Equity Offering in the amount of AUD 15 million.Imugene Limited has filed a Follow-on Equity Offering in the amount of AUD 15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,454,545 Price\Range: AUD 0.33공시 • Jul 14Imugene Limited Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCLImugene Limited announced new data from its Phase 1b clinical trial evaluating azer-cel (azercabtagene zapreleucel) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In February 2025, Imugene announced that a total of four out of seven patients had achieved a Complete Response (CR), defined as the disappear of all signs of cancer in response to treatment. Azer-cel is being developed as a potential allogeneic, off-the-shelf, CAR T-cell therapy, addressing key limitations of approved autologous CAR T drugs, including geographical access to treatment centres, manufacturing complexity and time to receive treatment (on-demand). Based on the updated response rate and maturing durability data, as well as having been awarded FDA Fast Track Designation for DLBCL in March 2025, Imugene will request a Type B (End of Phase 1) Meeting in Fourth Quarter 2025, with the US FDA to present the data and to discuss designs for a pivotal /registrational trial for azer-cel. The azer-cel allogeneic CAR T trial is an ongoing, open-label, multi-centre Phase 1b clinical trial in the U.S. and Australia, for CAR T relapsed patients with DLBCL. Treatment with azer-cel, lymphodepletion (LD) and IL-2 is showing promising results with evidence of meaningful clinical activity, and durability of response.공시 • Mar 04+ 1 more updateImugene Limited Announces CFO ChangesImugene Limited announced the appointment of Darren Keamy as the Company's Chief Financial Officer (CFO) starting 4 March 2025. Mr. Keamy is an experienced finance executive with a career spanning over 25 years in corporate finance, financial strategy, and investor relations within the biopharmaceutical industry. Prior to joining Imugene, he served as Chief Financial Officer and Company Secretary at Clinuvel Pharmaceuticals Ltd. from 2005 to 2024, where he played a pivotal role in the company’s transformation from a small biotech start-up to a cash generating, profitable, multinational, ASX-listed organisation. His expertise extends across corporate governance, risk management, financial reporting, and international expansion, having established legal and operational frameworks in multiple jurisdictions including the US, Switzerland, Singapore, Ireland, Monaco, and the UK. His commercial acumen has been pivotal in optimising financial strategies, enhancing operational efficiencies, and navigating complex regulatory environments. Before joining Clinuvel, Mr. Keamy held various financial leadership roles within global packaging specialists Amcor Limited, as well as Salomon Smith Barney (now part of Citigroup) and Superdrug Stores Plc in the UK. His extensive experience across finance, risk management, and compliance has equipped him with a deep understanding of complex financial structures and international business operations. Mr. Keamy holds a Bachelor of Commerce (Accounting) from La Trobe University, is a Certified Practising Accountant (CPA), and qualified Company Secretary having obtained a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia. Mr. Keamy replaces Mike Tonroe, who is resigning from his position as CFO.Breakeven Date Change • Nov 15No longer forecast to breakevenThe 3 analysts covering Imugene no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$150.9m in 2027. New consensus forecast suggests the company will make a loss of AU$50.5m in 2027.공시 • Nov 15Imugene Limited Announces Retirement of Jens Eckstein as Non-Executive DirectorImugene Limited announced Jens Eckstein has resigned from his position as a non-executive director of the company to focus on his other business interests. Jens has been a valued member of the company's board since May 2019, providing extensive insights and guidance to the company.공시 • Oct 14Imugene Limited, Annual General Meeting, Nov 14, 2024Imugene Limited, Annual General Meeting, Nov 14, 2024. Location: mccullough robertson, level 32, 25 martin place, sydney, nsw 2000 AustraliaNew Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$111m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$111m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Revenue is less than US$5m (AU$5.0m revenue, or US$3.3m).공시 • Sep 03Imugene Limited Announces Promising Results from its Phase 1b Clinical Trial with Azer-CelImugene Limited announced promising results from its Phase 1b clinical trial with azer-cel (azercabtagene zapreleucel, an allogeneic off-the-shelf CD19 CAR T), in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin's lymphoma (NHL). All enrolled patients had cancer that had returned following autologous CAR T therapy, a high unmet need for this patient population. Patients in the trial are being recruited across 15 leading cancer centres in the U.S. including, Columbia University, University of Minnesota, Emory, and Moffitt Cancer Centres and plans are ongoing to open up to 5 sites in Australia. Results: Evaluable: patients who qualify for at least their first 28-day scan; Overall response rate (ORR): the percentage of people in the study who have a complete response (CR) or partial response (PR) to the treatment as confirmed by scan; Responses: a complete response (CR) is defined as disappearance of all tumours; a partial response (PR) is defined as a reduction in tumours as confirmed by scan; Durability of Response (DOR): how long responses last. Nine (9) patients total from Cohorts A and B are considered evaluable (qualified for at least day 28 scan). One (1) patient (Cohort B) has been treated and is awaiting their 28-day scan: Of the 6 evaluable patients in Cohort A: 1 CR, 1 PR = 33% Overall Response Rate (ORR);1 CR = 17% CR; Durability of response was < 60 days; All patients no longer on trial. Of the 3 evaluable patients in Cohort B: 2 CRs = 67% ORR; 2 CRs = 67% CR; 1 Stable Disease (SD): On PET/CT scan imaging, patient’s tumour has decreased however, due to potential T-cell infiltration, noted an increase in signal intensity. This could represent pseudoprogression. The patient remains on trial and continues to be assessed for response at the follow up scans. Durability of response thus far: >120 days and >90 days (all patients are ongoing) All 4 patients (including 1 patient awaiting 28-day scan) continue on trial. The company will continue to enrol additional patients in Cohort B and follow patients for durability of response with the goal of providing a comprehensive package to the FDA for the potential Phase 2/3 registrational trial. Subject to patient recruitment, the company aims to provide an interim Phase 1b data update. If successful, azer-cel has the potential to become the first approved allogeneic CAR T cell therapy for blood cancer. Beyond studying its efficacy in blood cancers, in the future, Imugene plans to combine azer-cel with its novel onCARlytics program for the treatment of patients with solid tumours, opening a potentially large market for azer-cel in the 90% of cancer not classified as blood cancers.New Risk • Sep 01New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$111m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$111m). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).Breakeven Date Change • Jun 30Forecast to breakeven in 2027The 3 analysts covering Imugene expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$150.9m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Board Change • Jun 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Jens Eckstein was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측DB:ILA - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/2028N/A-26-22-2216/30/2027N/A-42-32-3216/30/2026N/A-55-43-43112/31/20254-59-67-63N/A9/30/20254-64-78-69N/A6/30/20254-69-90-76N/A3/31/20251-99-97-84N/A12/31/2024-2-129-104-92N/A9/30/20242-139-110-97N/A6/30/20245-150-115-102N/A3/31/202410-119-93-80N/A12/31/202315-89-70-59N/A9/30/202313-64-51-45N/A6/30/202312-38-31-31N/A3/31/202312-39-37-37N/A12/31/202212-40-42-42N/A9/30/202213-39-36-36N/A6/30/202213-38-31-31N/A3/31/202211-33-27-25N/A12/31/20218-27-24-20N/A9/30/20218-23-21-16N/A6/30/20217-18-19-13N/A3/31/20217-15-16-12N/A12/31/20206-12-12-11N/A9/30/20205-11-12-11N/A6/30/20204-11-12-10N/A3/31/20205-10-11-10N/A12/31/20195-9-10-9N/A9/30/20195-8N/A-8N/A6/30/20194-8N/A-8N/A3/31/20193-7N/A-7N/A12/31/20183-6N/A-6N/A9/30/20182-5N/A-5N/A6/30/20182-4N/A-5N/A3/31/20181-3N/A-4N/A12/31/20171-3N/A-3N/A9/30/20171-3N/A-3N/A6/30/20171-3N/A-3N/A3/31/20171-3N/A-3N/A12/31/20162-3N/A-3N/A9/30/20162-3N/A-3N/A6/30/20162-3N/A-3N/A3/31/20161-3N/A-2N/A12/31/20151-2N/A-2N/A9/30/20151-2N/A-2N/A6/30/20151-2N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ILA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: ILA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: ILA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: ILA 은(는) 내년에 수익이 없을 것으로 예상됩니다.고성장 매출: ILA 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ILA는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 20:48종가2026/05/21 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Imugene Limited는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관John HesterBell PotterDennis HulmeEdison Investment ResearchNaheed RahmanRaaS Advisory Pty Ltd
Breakeven Date Change • Nov 15No longer forecast to breakevenThe 3 analysts covering Imugene no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$150.9m in 2027. New consensus forecast suggests the company will make a loss of AU$50.5m in 2027.
Breakeven Date Change • Jun 30Forecast to breakeven in 2027The 3 analysts covering Imugene expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$150.9m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Lesley Cooper was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 30Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 35,445,999 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,220,668 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Mar 11+ 1 more updateImugene Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million.Imugene Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,444 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0072 Security Features: Attached Options
공시 • Jan 02Imugene Limited Announces Resignation of Dr. Bradley Glover as Chief Operating OfficerImugene Limited announced that Dr. Bradley Glover has resigned from his position as Chief Operating Officer of Imugene to focus on his other business interests. The Company will manage the transition of responsibilities with no impact on business operations or ongoing programs.
공시 • Oct 14Imugene Limited, Annual General Meeting, Nov 13, 2025Imugene Limited, Annual General Meeting, Nov 13, 2025. Location: at automic pty ltd, level 5, 126 phillip street, sydney nsw 2000 Australia
공시 • Jul 16+ 1 more updateImugene Limited has filed a Follow-on Equity Offering in the amount of AUD 15 million.Imugene Limited has filed a Follow-on Equity Offering in the amount of AUD 15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,454,545 Price\Range: AUD 0.33
공시 • Jul 14Imugene Limited Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCLImugene Limited announced new data from its Phase 1b clinical trial evaluating azer-cel (azercabtagene zapreleucel) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In February 2025, Imugene announced that a total of four out of seven patients had achieved a Complete Response (CR), defined as the disappear of all signs of cancer in response to treatment. Azer-cel is being developed as a potential allogeneic, off-the-shelf, CAR T-cell therapy, addressing key limitations of approved autologous CAR T drugs, including geographical access to treatment centres, manufacturing complexity and time to receive treatment (on-demand). Based on the updated response rate and maturing durability data, as well as having been awarded FDA Fast Track Designation for DLBCL in March 2025, Imugene will request a Type B (End of Phase 1) Meeting in Fourth Quarter 2025, with the US FDA to present the data and to discuss designs for a pivotal /registrational trial for azer-cel. The azer-cel allogeneic CAR T trial is an ongoing, open-label, multi-centre Phase 1b clinical trial in the U.S. and Australia, for CAR T relapsed patients with DLBCL. Treatment with azer-cel, lymphodepletion (LD) and IL-2 is showing promising results with evidence of meaningful clinical activity, and durability of response.
공시 • Mar 04+ 1 more updateImugene Limited Announces CFO ChangesImugene Limited announced the appointment of Darren Keamy as the Company's Chief Financial Officer (CFO) starting 4 March 2025. Mr. Keamy is an experienced finance executive with a career spanning over 25 years in corporate finance, financial strategy, and investor relations within the biopharmaceutical industry. Prior to joining Imugene, he served as Chief Financial Officer and Company Secretary at Clinuvel Pharmaceuticals Ltd. from 2005 to 2024, where he played a pivotal role in the company’s transformation from a small biotech start-up to a cash generating, profitable, multinational, ASX-listed organisation. His expertise extends across corporate governance, risk management, financial reporting, and international expansion, having established legal and operational frameworks in multiple jurisdictions including the US, Switzerland, Singapore, Ireland, Monaco, and the UK. His commercial acumen has been pivotal in optimising financial strategies, enhancing operational efficiencies, and navigating complex regulatory environments. Before joining Clinuvel, Mr. Keamy held various financial leadership roles within global packaging specialists Amcor Limited, as well as Salomon Smith Barney (now part of Citigroup) and Superdrug Stores Plc in the UK. His extensive experience across finance, risk management, and compliance has equipped him with a deep understanding of complex financial structures and international business operations. Mr. Keamy holds a Bachelor of Commerce (Accounting) from La Trobe University, is a Certified Practising Accountant (CPA), and qualified Company Secretary having obtained a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia. Mr. Keamy replaces Mike Tonroe, who is resigning from his position as CFO.
Breakeven Date Change • Nov 15No longer forecast to breakevenThe 3 analysts covering Imugene no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$150.9m in 2027. New consensus forecast suggests the company will make a loss of AU$50.5m in 2027.
공시 • Nov 15Imugene Limited Announces Retirement of Jens Eckstein as Non-Executive DirectorImugene Limited announced Jens Eckstein has resigned from his position as a non-executive director of the company to focus on his other business interests. Jens has been a valued member of the company's board since May 2019, providing extensive insights and guidance to the company.
공시 • Oct 14Imugene Limited, Annual General Meeting, Nov 14, 2024Imugene Limited, Annual General Meeting, Nov 14, 2024. Location: mccullough robertson, level 32, 25 martin place, sydney, nsw 2000 Australia
New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$111m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$111m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Revenue is less than US$5m (AU$5.0m revenue, or US$3.3m).
공시 • Sep 03Imugene Limited Announces Promising Results from its Phase 1b Clinical Trial with Azer-CelImugene Limited announced promising results from its Phase 1b clinical trial with azer-cel (azercabtagene zapreleucel, an allogeneic off-the-shelf CD19 CAR T), in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin's lymphoma (NHL). All enrolled patients had cancer that had returned following autologous CAR T therapy, a high unmet need for this patient population. Patients in the trial are being recruited across 15 leading cancer centres in the U.S. including, Columbia University, University of Minnesota, Emory, and Moffitt Cancer Centres and plans are ongoing to open up to 5 sites in Australia. Results: Evaluable: patients who qualify for at least their first 28-day scan; Overall response rate (ORR): the percentage of people in the study who have a complete response (CR) or partial response (PR) to the treatment as confirmed by scan; Responses: a complete response (CR) is defined as disappearance of all tumours; a partial response (PR) is defined as a reduction in tumours as confirmed by scan; Durability of Response (DOR): how long responses last. Nine (9) patients total from Cohorts A and B are considered evaluable (qualified for at least day 28 scan). One (1) patient (Cohort B) has been treated and is awaiting their 28-day scan: Of the 6 evaluable patients in Cohort A: 1 CR, 1 PR = 33% Overall Response Rate (ORR);1 CR = 17% CR; Durability of response was < 60 days; All patients no longer on trial. Of the 3 evaluable patients in Cohort B: 2 CRs = 67% ORR; 2 CRs = 67% CR; 1 Stable Disease (SD): On PET/CT scan imaging, patient’s tumour has decreased however, due to potential T-cell infiltration, noted an increase in signal intensity. This could represent pseudoprogression. The patient remains on trial and continues to be assessed for response at the follow up scans. Durability of response thus far: >120 days and >90 days (all patients are ongoing) All 4 patients (including 1 patient awaiting 28-day scan) continue on trial. The company will continue to enrol additional patients in Cohort B and follow patients for durability of response with the goal of providing a comprehensive package to the FDA for the potential Phase 2/3 registrational trial. Subject to patient recruitment, the company aims to provide an interim Phase 1b data update. If successful, azer-cel has the potential to become the first approved allogeneic CAR T cell therapy for blood cancer. Beyond studying its efficacy in blood cancers, in the future, Imugene plans to combine azer-cel with its novel onCARlytics program for the treatment of patients with solid tumours, opening a potentially large market for azer-cel in the 90% of cancer not classified as blood cancers.
New Risk • Sep 01New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$111m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$111m). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
Breakeven Date Change • Jun 30Forecast to breakeven in 2027The 3 analysts covering Imugene expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$150.9m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Board Change • Jun 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Jens Eckstein was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.